A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio N Tech Se stock. As of the latest transaction made, Citadel Advisors LLC holds 207,300 shares of BNTX stock, worth $23.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
207,300
Previous 126,000 64.52%
Holding current value
$23.1 Million
Previous $11.6 Million 43.32%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$80.36 - $102.87 $33.2 Million - $42.5 Million
-412,668 Reduced 86.17%
66,212 $5.32 Million
Q1 2024

May 15, 2024

BUY
$88.96 - $112.35 $39.9 Million - $50.4 Million
448,933 Added 1499.09%
478,880 $44.2 Million
Q4 2023

Feb 14, 2024

SELL
$90.91 - $112.75 $2.56 Million - $3.18 Million
-28,199 Reduced 48.5%
29,947 $3.16 Million
Q3 2023

Nov 14, 2023

SELL
$98.5 - $125.08 $13.4 Million - $17 Million
-136,062 Reduced 70.06%
58,146 $6.32 Million
Q2 2023

Aug 14, 2023

BUY
$102.58 - $129.66 $19.2 Million - $24.3 Million
187,519 Added 2803.39%
194,208 $21 Million
Q1 2023

May 15, 2023

SELL
$122.57 - $153.67 $15.4 Million - $19.3 Million
-125,602 Reduced 94.94%
6,689 $833,000
Q4 2022

Feb 14, 2023

BUY
$118.43 - $186.05 $12.9 Million - $20.2 Million
108,750 Added 461.96%
132,291 $19.9 Million
Q3 2022

Nov 14, 2022

SELL
$127.65 - $183.11 $33.7 Million - $48.4 Million
-264,344 Reduced 91.82%
23,541 $3.18 Million
Q2 2022

Aug 15, 2022

BUY
$123.25 - $186.24 $14.4 Million - $21.8 Million
116,888 Added 68.36%
287,885 $42.9 Million
Q1 2022

May 16, 2022

SELL
$126.25 - $231.85 $8.87 Million - $16.3 Million
-70,295 Reduced 29.13%
170,997 $29.2 Million
Q4 2021

Feb 14, 2022

SELL
$216.64 - $362.52 $7.76 Million - $13 Million
-35,808 Reduced 12.92%
241,292 $62.2 Million
Q3 2021

Nov 15, 2021

BUY
$205.93 - $447.23 $13.3 Million - $28.9 Million
64,532 Added 30.36%
277,100 $75.6 Million
Q2 2021

Aug 16, 2021

BUY
$113.32 - $241.49 $1.65 Million - $3.51 Million
14,535 Added 7.34%
212,568 $47.6 Million
Q1 2021

May 17, 2021

SELL
$85.73 - $119.5 $5.89 Million - $8.21 Million
-68,705 Reduced 25.76%
198,033 $21.6 Million
Q4 2020

Feb 16, 2021

BUY
$72.71 - $129.54 $9.03 Million - $16.1 Million
124,192 Added 87.12%
266,738 $21.7 Million
Q3 2020

Nov 16, 2020

SELL
$57.81 - $104.17 $12.3 Million - $22.1 Million
-212,615 Reduced 59.86%
142,546 $9.87 Million
Q2 2020

Aug 14, 2020

BUY
$38.58 - $66.74 $13.7 Million - $23.7 Million
355,161 New
355,161 $23.7 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.1B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.